CVS Group plc Director/PDMR Shareholding (8026Y)

TIDMCVSG

RNS Number : 8026Y

CVS Group plc

05 January 2024

5 January 2024

CVS Group Plc

("CVS" or the "Company")

Exercise of Options, PDMR Dealing

and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services, announces that on 4 January 2023, options over a total of 148,032 ordinary shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group 2020 SAYE Plan (2020/2024) and 6,733 Ordinary Shares under the CVS Group Long Term Incentive Plan 2020 ("LTIP 14") .

The sum of 148,032 new Ordinary Shares were issued to satisfy the balance of Ordinary Shares arising from the SAYE Exercise at an exercise price of GBP10.09. Admission of the 148,032 new Ordinary Shares has been satisfied by the Company's block listing admitted to the London Stock Exchange on 30 December 2021.

Robin Alfonso, Chief Financial Officer exercised options over 606 Ordinary Shares in the Company under the SAYE plan. The balance of the options were exercised by certain other employees and former employees of the Company.

Robin Alfonso additionally exercised options over 6,733 Ordinary Shares under the LTIP 14 scheme. The issuance of shares in connection with the LTIP 14 exercise was fully satisfied by 6,733 Ordinary Shares held by the CVS Group Employee Benefit Trust (the "EBT"). Following the exercise, a total of 47,945 Ordinary Shares are held by the EBT, representing approximately 0.067% of the Company's total voting rights.

Following his option exercises, Robin Alfonso holds a beneficial interest in 19,896 Ordinary Shares in the Company, representing approximately 0.028% of the total voting rights of the Company, calculated on the same basis.

Following the issue of the new Ordinary Shares, the Company has a total issued share capital of 71,685,694 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, following the issue of the new Ordinary Shares, the total number of voting rights in the Company will be 71,685,694. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Contacts:

CVS Group plc via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker) [phone]

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

Berenberg (Joint Broker) [phone]

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR)

Geoffrey Pelham-Lane [phone]

Ginny Pulbrook [phone]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Robin Alfonso 
     -------------------------------  ---------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status                  Chief Financial Officer 
     -------------------------------  ---------------------------------- 
 b)   Initial notification             Initial Notification 
       /Amendment 
     -------------------------------  ---------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                             CVS Group plc 
     -------------------------------  ---------------------------------- 
 b)   LEI                              213800J41XDQ2NX48O05 
     -------------------------------  ---------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 
 
 a)   Description of the financial   Ordinary shares of 0.2 pence each 
       instrument, type of 
       instrument                     GB00B2863827 
 
       Identification code 
 b)   Nature of the transaction           a) Exercise of options under the 2020 
                                           SAYE Plan (1 January 2024 maturity) 
                                           b) Exercise of options under the CVS 
                                           Group Long Term Incentive Plan 2020 
                                           (4 January 2024 maturity) 
     -----------------------------  ------------------------------------------- 
 c)   Price(s) and volume(s)         Price(s)       Volume 
                                        a) GBP10.09    a) 606 
                                         b) GBP0.002    b) 6,733 
     -----------------------------  ------------------------------------------- 
 d)   Aggregated information 
 
        *    Aggregated volume 
                                       7,339 
 
 
        *    Price                     GBP6,128.01 
     -----------------------------  ------------------------------------------- 
 e)   Date of the transaction        a) 4 January 2023 
                                      b) 4 January 2023 
     -----------------------------  ------------------------------------------- 
f)    Place of the transaction       a) London Stock Exchange - AIM 
                                      b) London Stock Exchange - AIM 
     -----------------------------  ------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAEFSEFNLEFA

(END) Dow Jones Newswires

January 05, 2024 05:25 ET (10:25 GMT)